Furaltadone suppresses IgE-mediated allergic response through the inhibition of Lyn/Syk pathway in mast cells

  • Eur J Pharmacol. 2018 Jun 5:828:119-125. doi: 10.1016/j.ejphar.2018.03.035.
Seung Taek Nam  1 ,  Hyun Woo Kim  1 ,  Hyuk Soon Kim  1 ,  Young Hwan Park  1 ,  Dajeong Lee  1 ,  Min Bum Lee  1 ,  Keun Young Min  1 ,  Young Mi Kim  2 ,  Wahn Soo Choi  3
Affiliations
  • 1. Department of Immunology, College of Medicine, Konkuk University, Chungju 27478, Republic of Korea.
  • 2. College of Pharmacy, Duksung Women's University, Seoul 01369, Republic of Korea. Electronic address: [email protected].
  • 3. Department of Immunology, College of Medicine, Konkuk University, Chungju 27478, Republic of Korea. Electronic address: [email protected].
PMID: 29588153 DOI: 10.1016/j.ejphar.2018.03.035
Abstract

Mast cells are critical cells that prompt various allergic response-inducing factors, contributing to allergic diseases. While used as an Antibiotic for livestock, there is no study on the effect of furaltadone on allergic response. This study investigated the effect of furaltadone on mast cells and passive cutaneous anaphylaxis (PCA). Furaltadone inhibited the degranulation of mast cells stimulated by antigen (IC50, ~ 3.9 μM), and also suppressed the production of tumor necrosis factor (TNF)-α and interleukin (IL)-4 in a concentration dependent manner. In addition, furaltadone inhibited allergic responses in an acute allergy animal model, PCA. Further investigation on the mechanism for these inhibitory effects of furaltadone found that the activities of Lyn/Syk and Syk-dependent downstream proteins such as mitogen-activated protein (MAP) kinases were inhibited by furaltadone in mast cells. Taken together, this study demonstrates that furaltadone inhibits the activation of mast cells by antigen via the suppression of the Lyn/Syk pathway and ameliorates allergic responses in vivo.

Keywords
Allergy; Furaltadone; Mast cells; Passive cutaneous anaphylaxis (PCA); Syk.
Products